Skip to main content
. 2020 Aug 31;2020:6372059. doi: 10.1155/2020/6372059

Table 2.

Effects of C. edulis on brain MDA, glutathione, catalase, AChE activity, and protein concentration of Scopolamine-treated mice.

Doses (mg/kg) MDA (mmol/g) Glutathione (mmol/g) Catalase (mmol H2O2/mg) AChE (mol/min/g) Protein (g/dl)
Control 63.61 ± 3.56 4.16 ± 0.36 290.56 ± 14.34 1.53 ± 0.04 5.96 ± 1.23
Scopo 1 105.46 ± 2.67### 1.63 ± 0.10## 108.58 ± 4.65### 2.45 ± 0.10## 5.85 ± 0.45
C. edulis 62.8 94.53 ± 5.06 2.16 ± 0.20 145.45 ± 7.80∗∗ 2.12 ± 0.12 6.31 ± 0.67
157 76.76 ± 3.14 3.86 ± 0.16 251.44 ± 32.55∗∗∗ 1.78 ± 0.07 6.04 ± 0.11
314 68.69 ± 3.87∗∗ 4.19 ± 0.27 274.36 ± 8.78∗∗∗ 1.47 ± 0.09∗∗ 6.12 ± 0.23
628 64.88 ± 4.47∗∗∗ 4.29 ± 0.09∗∗ 325.00 ± 18.89∗∗∗ 1.40 ± 0.11∗∗ 5.96 ± 0.78
Donepezil 5 60.38 ± 6.89∗∗∗ 4.47 ± 0.12∗∗ 423.60 ± 10.14∗∗∗ 1.31 ± 0.08∗∗∗ 6.29 ± 1.04

Each value represents the mean ± SEM (n = 5). The level of MDA increases and the antioxidant enzyme level decreases for the Scopolamine group (##p < 0.01, ###p < 0.001 vs. control), and the administration of C. edulis aqueous extract decreases the level of MDA by increasing the level of antioxidant enzymes (p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. Scopo). One-way ANOVA followed by the Tukey multiple comparison test. Scopo: Scopolamine.